Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9725413.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Heparin is the standard anticoagulant for patients undergoing cardiopulmonary bypass. There are some patients for whom heparin is unsuitable and ancrod (a defibrinogenating enzyme) has been used as an alternative. We present a patient with heparin-induced thrombocytopenia in whom treatment ancrod was ineffective. The addition of danaparoid sodium (a heparinoid) allowed safe cardiopulmonary bypass. We discuss the reasons for this and suggest that the combination of ancrod and danaparoid sodium is a logical one in such cases.
Medical subject headings
- Ancrod
- Anticoagulants
- Cardiopulmonary Bypass
- Chondroitin Sulfates
- Dermatan Sulfate
- Heparin
- Heparinoids
- Heparan Sulfate
- Thrombocytopenia